• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by MannKind Corporation

    3/27/26 10:34:42 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNKD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    MannKind Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    56400P706

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    56400P706


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MannKind Corp
    (b)Address of issuer's principal executive offices:

    30930 Russell Ranch Road, Suite 300, Westlake Village, CA, 91362
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $MNKD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNKD

    DatePrice TargetRatingAnalyst
    2/27/2026$3.50Outperform → Sector Perform
    RBC Capital Mkts
    11/24/2025Buy
    Truist
    11/13/2025$7.00Outperform
    Leerink Partners
    10/20/2025$10.00Overweight
    Wells Fargo
    10/10/2025$9.00Outperform
    Leerink Partners
    7/16/2025$9.00Buy
    H.C. Wainwright
    4/10/2025$12.00Outperform
    Mizuho
    2/10/2025$11.00Outperform
    Wedbush
    More analyst ratings

    $MNKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prentiss Christopher B

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/25/26 9:30:09 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Castagna Michael

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/25/26 9:30:07 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Singh Sanjay R

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/25/26 9:30:06 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

    Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1DData to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lu

    3/9/26 9:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Announces Settlement of Convertible Senior Notes

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock. About MannKindMannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize t

    3/5/26 4:30:00 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Participate in Upcoming Investor Conferences

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind's Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris Prentiss will participate in fireside chats and in 1x1 meetings with investors. Leerink Partners 2026 Global Healthcare Conference in MiamiTuesday, March 10, 3:40 p.m. ET Barclays 28th Annual Global Healthcare Conference in MiamiWednesday, March 11, 1:00 p.m. ET Links to the live audio webcast of the sessions will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/ev

    3/4/26 9:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mannkind downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Mannkind from Outperform to Sector Perform and set a new price target of $3.50

    2/27/26 8:29:08 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Mannkind

    Truist initiated coverage of Mannkind with a rating of Buy

    11/24/25 8:30:57 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Mannkind with a new price target

    Leerink Partners initiated coverage of Mannkind with a rating of Outperform and set a new price target of $7.00

    11/13/25 9:09:54 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by MannKind Corporation

    SCHEDULE 13G/A - MANNKIND CORP (0000899460) (Subject)

    3/27/26 10:34:42 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by MannKind Corporation

    10-K - MANNKIND CORP (0000899460) (Filer)

    2/26/26 8:06:57 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNKIND CORP (0000899460) (Filer)

    2/26/26 8:03:36 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Castagna Michael bought $259,000 worth of shares (100,000 units at $2.59), increasing direct ownership by 4% to 2,575,911 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/10/26 9:30:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Financials

    Live finance-specific insights

    View All

    MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026  DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reporte

    2/26/26 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to review the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay w

    2/18/26 9:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

    MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind's dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study participants, investigators, advisors, and clinical site teams for their invaluable contributions to the ICoN-1 studyMannKind will host a conference call today at 9:00 AM EST to discuss this update in mo

    11/10/25 8:00:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Leadership Updates

    Live Leadership Updates

    View All

    MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD, Chief Executive Officer, and will serve on the company's executive leadership team. "Ajay's deep expertise in medical affairs, clinical development, and global strategy—combined with his background as a practicing physician—will be instrumental as we continue to advance o

    9/29/25 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    1/5/22 6:05:00 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/13/24 5:08:11 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    1/22/24 12:56:57 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MannKind Corporation (Amendment)

    SC 13G/A - MANNKIND CORP (0000899460) (Subject)

    2/9/23 11:25:13 AM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care